Pacira Pharmaceuticals buy Truist Financial Co.
Start price
25.07.25
/
50%
€18.90
Target price
25.07.26
€25.55
Performance (%)
-11.11%
Price
06.02.26
€16.40
Summary
This prediction is currently active. The prediction for Pacira Pharmaceuticals disappoints with a performance of -11.11%. This prediction currently runs until 25.07.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Pacira Pharmaceuticals | -7.345% | -7.345% |
| iShares Core DAX® | 1.001% | -1.218% |
| iShares Nasdaq 100 | -1.447% | -4.597% |
| iShares Nikkei 225® | 8.406% | 8.425% |
| iShares S&P 500 | -0.226% | -2.451% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at Truist Financial Corporation from a "hold" rating to a "buy" rating. They now have a $30.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€19.10
07.11.25
07.11.25
€24.27
07.11.26
07.11.26
-7.33%
06.02.26
06.02.26
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€18.40
25.07.24
25.07.24
€27.62
25.07.25
25.07.25
2.17%
26.07.25
26.07.25